类有机物
免疫系统
免疫疗法
流式细胞术
癌症研究
细胞毒性T细胞
生物
无容量
细胞毒性
细胞培养
外周血单个核细胞
癌症免疫疗法
免疫学
体外
细胞生物学
生物化学
遗传学
作者
Guoying Zhou,Ruby Lieshout,Gilles van Tienderen,Valeska de Ruiter,Martin E. van Royen,Patrick P.C. Boor,Luc Magré,Jyaysi Desai,Kübra Köten,Yik Yang Kan,Zhouhong Ge,Lucia Campos Carrascosa,Cecile Geuijen,Dave Sprengers,Luc J. W. van der Laan,M Verstegen,Jaap Kwekkeboom
标识
DOI:10.1038/s41416-022-01839-x
摘要
Immunotherapy with immune checkpoint inhibitors (ICIs) is being explored to improve cholangiocarcinoma (CCA) therapy. However, it remains difficult to predict which ICI will be effective for individual patients. Therefore, the aim of this study is to develop a co-culture method with patient-derived CCA organoids and immune cells, which could represent anti-cancer immunity in vitro.CCA organoids were co-cultured with peripheral blood mononuclear cells or T cells. Flow cytometry, time-lapse confocal imaging for apoptosis, and quantification of cytokeratin 19 fragment (CYFRA) release were applied to analyse organoid and immune cell behaviour. CCA organoids were also cultured in immune cell-conditioned media to analyse the effect of soluble factors.The co-culture system demonstrated an effective anti-tumour organoid immune response by a decrease in live organoid cells and an increase in apoptosis and CYFRA release. Interpatient heterogeneity was observed. The cytotoxic effects could be mediated by direct cell-cell contact and by release of soluble factors, although soluble factors only decreased viability in one organoid line.In this proof-of-concept study, a novel CCA organoid and immune cell co-culture method was established. This can be the first step towards personalised immunotherapy for CCA by predicting which ICIs are most effective for individual patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI